Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Drug

Proheal Pharmaceuticals Initiates Clinical Study for PHP1003 in Thyroid-Associated Ophthalmopathy

Fineline Cube Oct 28, 2022

Proheal Pharmaceuticals, a Suzhou-based developer of drugs for ophthalmology and autoimmune diseases, announced the first...

Company Drug

HutchMed Initiates Phase II/III Study for Elunate and Tyvyt in Renal Cell Carcinoma

Fineline Cube Oct 28, 2022

China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase...

Company

Shanghai Pharmaceuticals Reports 12.86% YOY Revenue Growth in Q3 2022

Fineline Cube Oct 28, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) released its Q3 2022 financial report, recording RMB 62.904...

Company Drug

Recbio’s Neoadjuvant HPV Vaccine Accepted for Review by NMPA

Fineline Cube Oct 28, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced that a clinical trial...

Company Drug

Kintor Completes Enrollment for GT20029 Phase I Study in US

Fineline Cube Oct 28, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of enrollment for a Phase I...

Company Drug

Alphamab Oncology Gains NMPA Approval for JSKN003 Clinical Trial

Fineline Cube Oct 28, 2022

Alphamab Oncology (HKG: 9966) announced that it has received approval from the National Medical Products...

Company Drug

WinHealth’s Ravicti Receives Orphan Drug Designation in Taiwan

Fineline Cube Oct 28, 2022

China-based Hong Kong WinHealth Pharma Group Ltd announced that its Swiss partner Immedica Pharma AB’s...

Company Drug

Lee’s Pharmaceutical’s NVK-002 Shows Strong Results in Phase III CHAMP Study

Fineline Cube Oct 28, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced that...

Company Drug

CSPC’s Antibody-Drug Conjugate SYS6002 Gains CDE Approval for Clinical Study

Fineline Cube Oct 28, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...

Company

Luye Pharma’s Long-Acting IL-4Rα Antibody BA2101 Gains CDE Approval

Fineline Cube Oct 28, 2022

China-based Luye Pharma Group (HKG: 2186) announced that its controlling subsidiary Shandong Boan Biotechnology Co.,...

Company Drug

Ausper Biopharma’s COVID-19 Nasal Spray Antibody Gets NMPA Approval

Fineline Cube Oct 28, 2022

Ausper Biopharma Inc., a Hangzhou-based developer of hepatitis B virus (HBV) drugs, announced that its...

Company

Merck’s Q3 Sales Rise on Key Drug Performances, China Growth

Fineline Cube Oct 28, 2022

US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) reported its Q3 2022 financial results,...

Company Deals

Salubris Partners with Anlong Bio for Small Nucleic Acid Drugs in Hypertension

Fineline Cube Oct 28, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with Beijing...

Policy / Regulatory

Shanghai Launches Inhaled COVID-19 Vaccine Booster Program

Fineline Cube Oct 28, 2022

On October 25, Shanghai began accepting patient reservations for the inhalable recombinant COVID-19 vaccine (adenovirus...

Company Drug

Ocumension Initiates Second Phase III Denali Study for OT-301 in US

Fineline Cube Oct 27, 2022

China-based Ocumension Therapeutics (HKG: 1477) announced the initiation of a second Phase III Denali study...

Company R&D

Nankai University Establishes Postgraduate Practice Base with China Resources Biopharma

Fineline Cube Oct 27, 2022

The College of Pharmacy at Nankai University has established a postgraduate practice base at the...

Company Deals

Yiming and WZ Biosciences Collaborate on mRNA Process Platform

Fineline Cube Oct 27, 2022

China-based Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, and compatriot firm WZ...

Company Drug

BeiGene’s Brukinsa Receives Multiple Marketing Approvals in Latin America

Fineline Cube Oct 27, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced receiving multiple marketing approvals...

Company Drug

Zhaoke Ophthalmology Completes Enrollment for Intrarosa Phase III Trial

Fineline Cube Oct 27, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has completed...

Company Deals

JW Therapeutics Partners with 2seventy bio to Develop Cell Therapy Platform

Fineline Cube Oct 27, 2022

China-based JW Therapeutics (HKG: 2126) has entered into a partnership with US firm 2seventy bio...

Posts pagination

1 … 655 656 657 … 711

Recent updates

  • Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA
  • WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
  • China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration
  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Legal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

Company

WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%

Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.